cangrelor trial summary

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	1.04 [0.88 1.24]	p=1.00	0	7754	1	CHAMPION-PCI,
Cardiovascular death	no data
myocardial infarction (fatal and non fatal)	0.40 [0.12 1.27]	p=1.00	0	7754	1	CHAMPION-PCI,
stroke (fatal and non fatal)	0.85 [0.29 2.54]	p=1.00	0	7754	1	CHAMPION-PCI,
MACE	0.67 [0.40 1.14]	p=1.00	0	7754	1	CHAMPION-PCI,
All cause death	1.59 [0.52 4.87]	p=1.00	0	7754	1	CHAMPION-PCI,
Major bleeding	no data
net benefit	no data
stent thrombosis	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.87 [0.71 1.07]	p=1.00	0	5355	1	CHAMPION-PLATFORM,
Cardiovascular death	no data
myocardial infarction (fatal and non fatal)	0.91 [0.74 1.13]	p=1.00	0	5355	1	CHAMPION-PLATFORM,
stroke (fatal and non fatal)	1.15 [0.39 3.44]	p=1.00	0	5355	1	CHAMPION-PLATFORM,
MACE	no data
All cause death	no data
Major bleeding	no data
net benefit	no data
stent thrombosis	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

All type of patients: 1 trials - Bridge

No demonstrated result

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

suggested cardiovascular events by 20% (not demonstrated)

suggested MACE by 20% (not demonstrated)

suggested net benefit by 20% (not demonstrated)

suggested stent thrombosis by 38% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.80 [0.67 0.94]	p=0.04	0	10942	1	CHAMPION PHOENIX,
Cardiovascular death	1.00 [0.52 1.92]	p=1.00	0	10942	1	CHAMPION PHOENIX,
myocardial infarction (fatal and non fatal)	0.81 [0.67 0.98]	p=0.04	0	10942	1	CHAMPION PHOENIX,
stroke (fatal and non fatal)	no data
MACE	0.80 [0.67 0.94]	p=0.04	0	10942	1	CHAMPION PHOENIX,
All cause death	1.00 [0.52 1.92]	p=1.00	0	10942	1	CHAMPION PHOENIX,
Major bleeding	1.50 [0.53 4.22]	p=1.00	0	10942	1	CHAMPION PHOENIX,
net benefit	0.80 [0.68 0.94]	p=0.04	0	10942	1	CHAMPION PHOENIX,
stent thrombosis	0.62 [0.43 0.90]	p=0.04	0	10942	1	CHAMPION PHOENIX,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	1.04 [0.88 1.24]	p=1.00	0	7754	1	CHAMPION-PCI,
Cardiovascular death	no data
myocardial infarction (fatal and non fatal)	0.40 [0.12 1.27]	p=1.00	0	7754	1	CHAMPION-PCI,
stroke (fatal and non fatal)	0.85 [0.29 2.54]	p=1.00	0	7754	1	CHAMPION-PCI,
MACE	0.67 [0.40 1.14]	p=1.00	0	7754	1	CHAMPION-PCI,
All cause death	1.59 [0.52 4.87]	p=1.00	0	7754	1	CHAMPION-PCI,
Major bleeding	no data
net benefit	no data
stent thrombosis	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.87 [0.71 1.07]	p=1.00	0	5355	1	CHAMPION-PLATFORM,
Cardiovascular death	no data
myocardial infarction (fatal and non fatal)	0.91 [0.74 1.13]	p=1.00	0	5355	1	CHAMPION-PLATFORM,
stroke (fatal and non fatal)	1.15 [0.39 3.44]	p=1.00	0	5355	1	CHAMPION-PLATFORM,
MACE	no data
All cause death	no data
Major bleeding	no data
net benefit	no data
stent thrombosis	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Stable and unstable ACS: 1 trials - CHAMPION-PCI

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	1.04 [0.88 1.24]	p=1.00	0	7754	1	CHAMPION-PCI,
Cardiovascular death	no data
myocardial infarction (fatal and non fatal)	0.40 [0.12 1.27]	p=1.00	0	7754	1	CHAMPION-PCI,
stroke (fatal and non fatal)	0.85 [0.29 2.54]	p=1.00	0	7754	1	CHAMPION-PCI,
MACE	0.67 [0.40 1.14]	p=1.00	0	7754	1	CHAMPION-PCI,
All cause death	1.59 [0.52 4.87]	p=1.00	0	7754	1	CHAMPION-PCI,
Major bleeding	no data
net benefit	no data
stent thrombosis	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Cangrelor antiplatelets drug